[Form 4] CorMedix Inc. Insider Trading Activity

Rhea-AI Filing Summary

CorMedix Inc. (CRMD) Chief Legal Officer Beth Zelnick Kaufman received a grant of 69,686 restricted stock units on 08/29/2025, reported on Form 4. Each unit converts to one share and was granted at no cash price ($0). Following the grant, Ms. Zelnick Kaufman beneficially owned 189,298 shares. The restricted stock units vested 1/4 immediately on the grant date and the remainder in three equal annual installments on each anniversary, subject to continued employment. The Form 4 was signed and dated 09/03/2025.

Insights

Compensation Analyst

TL;DR: A standard, time‑based RSU grant to the Chief Legal Officer aligns compensation with retention and long‑term equity incentives.

The Form 4 documents a customary executive equity award: 69,686 restricted stock units with 25% vesting at grant and the balance vesting annually over three years. The award was granted at $0, indicating stock‑based compensation rather than a purchase. Such grants are typical for retention and alignment of executive interests with shareholders. The disclosed post‑grant beneficial ownership of 189,298 shares provides context on the officer's stake but does not by itself indicate a material change to company control or capital structure.

Corporate Governance Expert

TL;DR: Disclosure is routine and complies with Section 16 reporting; the vesting schedule reflects time‑based retention terms.

The filing shows clear disclosure of the grant date, quantity, consideration ($0), and vesting schedule, meeting Form 4 requirements. The immediate 1/4 vesting at grant is a notable detail for governance review because it accelerates part of the compensation value to the officer. No derivative transactions or sales are reported. Based on the information presented, this is a non‑transactional compensation disclosure rather than an event with material governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zelnick Kaufman Beth

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		A		69,686	A	$0(1)	189,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units granted on 08/29/2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vested 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

	/s/ Beth Zelnick Kaufman	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beth Zelnick Kaufman receive according to the CRMD Form 4?

She was granted 69,686 restricted stock units on 08/29/2025, each convertible to one share of CorMedix common stock.

What was the cost to Beth Zelnick Kaufman for the RSU grant reported on Form 4 (CRMD)?

The restricted stock units were granted at $0 consideration, as disclosed in the filing.

How many shares does Beth Zelnick Kaufman beneficially own after the reported transaction?

Following the grant, she beneficially owned 189,298 shares of CorMedix common stock.

What is the vesting schedule for the RSUs granted to the Chief Legal Officer (CRMD)?

The RSUs vested 1/4 on the grant date, then 1/4 on each of the next three anniversaries, subject to continued employment.

When was the Form 4 for this insider grant signed and filed?

The Form 4 was signed by Beth Zelnick Kaufman on 09/03/2025 and reports the transaction dated 08/29/2025.